Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer

Annemieke H. Ackerstaff, Coen R.N. Rasch, Alfons J.M. Balm, Jan Paul De Boer, Ruud Wiggenraad, Derek H.F. Rietveld, R. Theo Gregor, Robert Kröger, Michael Hauptmann, Andrew Vincent, Frans J.M. Hilgers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background. The purpose of this investigation was to present 5-years of quality-of-life (QOL) results of a multicenter randomized phase III trial, assessing intra-arterial (IA) versus standard intravenous (IV) chemoradiation for inoperable stage IV head and neck cancer. Methods. Evaluation of 71 patients through European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module (EORTC QLQ-C30) and Head and Neck Module (QLQ-H&N35), and trial-specific questionnaires. Treatment consisted of standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. Results. No significant differences in treatment-related QOL problems between 1 and 5 years posttreatment were observed, except for "dry mouth" (gradually improving; p = .004). Survivors have lower fatigue levels (p = .04), better voice (p = 0.3), and swallowing (p = .03) than patients who could not complete all subsequent follow-up questionnaires. Conclusions. Most treatment-related QOL issues deteriorate during treatment, improve in the first year, and then remain stable, except xerostomia, improving up to the 5-year assessment point. Survivors show more positive scores for fatigue, voice, and swallowing. QOL issues at 1 year, thus, for most already represent those after 5-year follow-up.

Original languageEnglish
Pages (from-to)974-980
Number of pages7
JournalHead and Neck
Volume34
Issue number7
DOIs
Publication statusPublished - 1 Jul 2012

Cite this